The story of Sildenafil presents a interesting case for investors in the medicinal sector. While initially a blockbuster success, generating vast sums, the intellectual property end and the subsequent entry of off-brand competitors have significantly affected revenue. This poses questions about the long-term viability of related therapeutic inno… Read More